ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in ...

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

Rusfertide maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks in the VERIFY study. Patients switching from placebo to rusfertide showed rapid ...

Stage 1 PV management includes phlebotomy, low-dose aspirin, cytoreductive therapy, and lifestyle changes to prevent complications. Stage 1 polycythemia vera is manageable with monitoring, phlebotomy, ...

This article was reviewed by Felix Gussone, MD. How to Read Blood Test Results: What “Normal” Really Means for Your Health ...

Patients with polycythemia vera (PV) taking the investigational therapy rusfertide were able to largely maintain hematocrit control and avoid the need for phlebotomy over 52 weeks, according to ...

A 27-year-old man faces animal cruelty charges after a traffic stop revealed a malnourished dog in his car. The dog, Sprout, ...

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit ...

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients ...

(Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, announced today that a leading Northeastern U.S. children’s hospital has ...

Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs December 7, 2025 ...